DPP-4/SGLT2 Inhibitor Combined Therapy for Type 2 Diabetes

Prescriber - United Kingdom
doi 10.1002/psb.1626
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Qtern: DPP-4 and SGLT2 Inhibitor Combination for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Ertugliflozin: A New SGLT2 Inhibitor for Type 2 Diabetes

Prescriber
Pharmacology
2019English

Emerging DPP-4 Inhibitors: Focus on Linagliptin for Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2013English

Effective SGLT2 Inhibitor for Patient With Type 2 Diabetes Mellitus (T2DM) and Depression

2020English

Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
2016English

DPP-4 Inhibitor and Alpha-Glucosidase Inhibitor Equally Improve Endothelial Function in Patients With Type 2 Diabetes: EDGE Study

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

Empagliflozin: A New Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Drugs in Context
Molecular MedicinePharmacology
2014English

Use of DPP-4 Inhibitors in Type 2 Diabetes: Focus on Sitagliptin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2010English

SGLT2 Inhibitor Ipragliflozin Alone and Combined With Pioglitazone Prevents Progression of Nonalcoholic Steatohepatitis in a Type 2 Diabetes Rodent Model

Physiological Reports
Physiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy